Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 28, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 27, 2023
Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group has by notice to Mendus requested the conversion of convertible bonds. | March 23, 2023
07.03.2023 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has closed a second loan under the terms of the commitment from its largest shareholder Van Herk .
Oxurion Receives Transparency Notification from Negma Group Leuven, BELGIUM, Boston, MA, US - March 2, 2023 - 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing